Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Edwards Lifesciences is a medical devices business based in the US. Edwards Lifesciences shares (EW) are listed on the NYSE and all prices are listed in US Dollars. Edwards Lifesciences employs 15,700 staff and has a trailing 12-month revenue of around $5.4 billion.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $76.70 |
|---|---|
| 52-week range | $67.13 - $131.10 |
| 50-day moving average | $75.28 |
| 200-day moving average | $90.77 |
| Wall St. target price | $91.09 |
| PE ratio | 33.2177 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.32 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $76.7 from 2023-01-31
| 1 week (2023-01-25) | -1.27% |
|---|---|
| 1 month (2022-12-30) | 2.80% |
| 3 months (2022-11-01) | 5.66% |
| 6 months (2022-08-01) | -22.88% |
| 1 year (2022-01-28) | -26.86% |
|---|---|
| 2 years (2021-02-01) | -6.37% |
| 3 years (2020-01-31) | 219.86 |
| 5 years (2018-02-01) | 126.98 |
Valuing Edwards Lifesciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Edwards Lifesciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Edwards Lifesciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Edwards Lifesciences shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Edwards Lifesciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0653. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Edwards Lifesciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Edwards Lifesciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.8 billion.
The EBITDA is a measure of a Edwards Lifesciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $5.4 billion |
|---|---|
| Operating margin TTM | 31.82% |
| Gross profit TTM | $4 billion |
| Return on assets TTM | 12.7% |
| Return on equity TTM | 2481.14% |
| Profit margin | 27.2% |
| Book value | $10.04 |
| Market capitalisation | $49.5 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Edwards Lifesciences.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.68
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Edwards Lifesciences's overall score of 21.68 (as at 12/31/2018) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Edwards Lifesciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.78/100
Edwards Lifesciences's environmental score of 4.78 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.43/100
Edwards Lifesciences's social score of 13.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Edwards Lifesciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.96/100
Edwards Lifesciences's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Edwards Lifesciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Edwards Lifesciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Edwards Lifesciences has, for the most part, managed to keep its nose clean.
Edwards Lifesciences Corp was last rated for ESG on: 2019-01-01.
| Total ESG score | 21.68 |
|---|---|
| Total ESG percentile | 24.1 |
| Environmental score | 4.78 |
| Environmental score percentile | 6 |
| Social score | 13.43 |
| Social score percentile | 6 |
| Governance score | 10.96 |
| Governance score percentile | 6 |
| Level of controversy | 2 |
We're not expecting Edwards Lifesciences to pay a dividend over the next 12 months.
Edwards Lifesciences's shares were split on a 3:1 basis on 31 May 2020. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Edwards Lifesciences shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Edwards Lifesciences shares which in turn could have impacted Edwards Lifesciences's share price.
Over the last 12 months, Edwards Lifesciences's shares have ranged in value from as little as $67.13 up to $131.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Edwards Lifesciences's is 1.008. This would suggest that Edwards Lifesciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
